Segall Bryant & Hamill LLC Sells 28,247 Shares of Phibro Animal Health Corporation $PAHC

Segall Bryant & Hamill LLC decreased its stake in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 18.8% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 121,898 shares of the company’s stock after selling 28,247 shares during the period. Segall Bryant & Hamill LLC’s holdings in Phibro Animal Health were worth $4,932,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in PAHC. Penserra Capital Management LLC purchased a new position in Phibro Animal Health during the third quarter valued at approximately $519,000. Capricorn Fund Managers Ltd purchased a new position in shares of Phibro Animal Health during the 3rd quarter valued at $10,233,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Phibro Animal Health during the 3rd quarter valued at $8,931,000. Bailard Inc. bought a new position in shares of Phibro Animal Health in the second quarter worth $259,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Phibro Animal Health in the second quarter worth $813,000. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Price Performance

Shares of Phibro Animal Health stock opened at $51.89 on Thursday. The firm has a market capitalization of $2.10 billion, a PE ratio of 23.06, a price-to-earnings-growth ratio of 0.80 and a beta of 0.74. The company has a current ratio of 3.05, a quick ratio of 1.22 and a debt-to-equity ratio of 2.14. Phibro Animal Health Corporation has a 12 month low of $16.16 and a 12 month high of $56.30. The business’s 50-day moving average price is $44.68 and its 200-day moving average price is $41.39.

Phibro Animal Health (NASDAQ:PAHC) last issued its earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.18. The business had revenue of $373.91 million during the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Sell-side analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th will be given a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 0.9%. The ex-dividend date is Wednesday, March 4th. Phibro Animal Health’s dividend payout ratio is presently 21.33%.

Insider Activity

In other news, CEO Jack Bendheim sold 110,842 shares of Phibro Animal Health stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $48.38, for a total value of $5,362,535.96. Following the transaction, the chief executive officer owned 122,958 shares in the company, valued at approximately $5,948,708.04. The trade was a 47.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 299,200 shares of company stock worth $14,249,723 over the last quarter. 50.13% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently commented on PAHC shares. JPMorgan Chase & Co. boosted their target price on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 9th. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. Finally, Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a research report on Friday, February 6th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $37.50.

Phibro Animal Health Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.